Opinion
Video
Author(s):
Clinical oncologists share their best practices for the utilization of PSMA-targeted agents in patients with prostate cancer.
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
Ultra-low PSA responses are more prevalent with darolutamide plus ADT
Dr. Murphy on increasing diversity in cancer clinical trials
Most men in EMBARK trial recover T levels following treatment suspension
TikTok, social media does more harm than good for prostate cancer education